Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 22 chart positions in 22 markets.
By chart position
- 🇺🇸US · Life Sciences#1095K to 30K
- 🇬🇧GB · Life Sciences#1735K to 30K
- 🇰🇷KR · Life Sciences#11100K to 300K
- 🇯🇵JP · Life Sciences#4230K to 100K
- 🇸🇪SE · Life Sciences#5110K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
86K to 282K🎙 Daily cadence·219 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
288K to 939K🇰🇷32%🇯🇵11%🇹🇼11%+19 more - Active Followers
Loyal subscribers who consistently listen
86K to 282K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 34 epsHosts
Recent guests
Recent episodes
Breaking borders: Building biotech scale in Benelux
Sep 3, 2026
Unknown duration
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
Sep 2, 2026
Unknown duration
Fragile X at a turning point: Breaking through the clinical bottleneck
Aug 27, 2026
Unknown duration
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
Aug 26, 2026
Unknown duration
Rewriting the rules of CMV prevention
Aug 20, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 9/3/26 |  Breaking borders: Building biotech scale in Benelux | In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We examine why Benelux delivers world‑class science yet remains an investment patchwork, and what it will take to knit the region into a truly unified biotech investment corridor.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsChristina Takke, Managing Partner, V-Bio VenturesMariette van der Velden-Roesink, Founding Partner, Curie CapitalDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. | — | ||||||
| 9/2/26 |  Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals | Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking pancreatic cancer drug; BioNTech suspends a mid-stage trial of its mRNA cancer immunotherapy after a futility analysis; and nine mid-sized biopharma companies join their big pharma peers in President Donald Trump’s Most Favored Nation drug pricing scheme. | — | ||||||
| 8/27/26 |  Fragile X at a turning point: Breaking through the clinical bottleneck | In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsHilary Rosselot, Executive Director, National Fragile X FoundationJordi Fàbrega, Co-Founder & CEO, CONNECTA TherapeuticsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. | — | ||||||
| 8/26/26 |  Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed | FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for their mRNA-based cancer vaccine; Trump nominates White House aide Heidi Overton as FDA commissioner; and the oral obesity market heats up with rivals Eli Lilly and Novo Nordisk going head-to-head. | — | ||||||
| 8/20/26 |  Rewriting the rules of CMV prevention | In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at Oxford University. We explore transplantation and antiviral innovation and why CMV remains one of the most persistent and consequential challenges facing transplant patients today.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsIan McGowan, CMO, SynklinoJames Hunter, Associate Professor of Transplantation, Oxford UniversityDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.Custom Fields | — | ||||||
| 8/19/26 |  Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more | Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide. | — | ||||||
| 8/13/26 |  The Italian inflection point: Clinical strength, culture and capital | In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at Angelini Ventures. We explore how Italy’s life sciences ecosystem has evolved over the last decade—from stronger tech transfer and growing venture capital to the gaps that still keep it from matching the UK, Germany or France in company creation and scale.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsDiana Saraceni, Founder and Managing Partner, Panakès PartnersFabrizio Calisti, Medical Director, Angelini VenturesDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. | — | ||||||
| 8/12/26 |  Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight | After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again. | — | ||||||
| 8/11/26 |  Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms | The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune. | — | ||||||
| 8/6/26 |  The next treatment-resistant depression paradigm | In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsHans Eriksson, Chief Medical Officer, FundaMental PharmaSteve Levine, Chief Patient Officer, Compass PathwaysDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/30/26 |  Life after the lead asset: Advancing an early-stage pipeline | In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively.This episode is presented in partnership with Arvinas. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestRandy Teel, President and CEO, Arvinas | — | ||||||
| 7/29/26 |  Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more | The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos. | — | ||||||
| 7/23/26 |  Nordic biotech’s next act: From fragmentation to global force | In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsEster Sklarsky, Principal, Sound BioventuresJoão Ribas, Partner, Novo Holdings Seed InvestmentsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. | — | ||||||
| 7/22/26 |  Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2 | Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues. | — | ||||||
| 7/16/26 | pain reliefopioid alternatives+3 | Lance AlstodtPaul Mieyal | Biorestorative TherapiesSouth Rampart Pharma | — | pain reliefopioid alternatives+3 | — | 19m 11s | ||
| 7/15/26 | neurodegenerative diseasepsychedelics+4 | — | antisense therapeuticBiogen+4 | — | Biogentau+8 | — | 21m 22s | ||
| 7/14/26 | job marketlife sciences+3 | Angela Gabriel | BioSpace | — | job marketlife sciences careers+3 | — | 9m 01s | ||
| 7/10/26 | gene editingbiologics manufacturing+4 | Jack CrawfordMagnus Gustavsson | DemetraNorthX Biologics | — | gene editingbiologics+5 | — | 20m 41s | ||
| 7/8/26 | M&A activityIPO trends+3 | — | Vertex PharmaceuticalsCrinetics+1 | — | Vertex PharmaceuticalsCrinetics+5 | — | 17m 04s | ||
| 7/1/26 | FDA changesdealmaking+4 | — | TavneosFDA+1 | San Diego | BIO 2026FDA+5 | — | 22m 54s | ||
| 6/25/26 | UK biotechlife sciences investment+4 | Hakan GokerMaina Bhaman | M VenturesSofinnova Partners | UKGolden Triangle | UK biotechGolden Triangle+5 | — | 19m 37s | ||
| 6/24/26 | M&A in biopharmaFDA regulatory updates+4 | — | IL-23 blockerDupixent+11 | — | biopharmaM&A+5 | — | 21m 36s | ||
| 6/18/26 | recessive dystrophic epidermolysis bullosacell therapy+3 | Mark LowdellVishwas Seshadri | INmuneBio IncAbeona Therapeutics | — | RDEBcell and gene therapy+3 | — | 21m 43s | ||
| 6/17/26 | Modernabiotech IPOs+4 | — | ModernaFDA+8 | — | ModernaFDA+5 | — | 25m 33s | ||
| 6/10/26 | biotech ecosystemlife sciences investment+4 | Hannah FranklinPablo Gabriel Cironi Lopez | Biovance CapitalCaixa Capital Risc | PortugalSpain+1 | biotechinvestment+6 | — | 20m 33s | ||
Showing 25 of 207
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for BioSpace
Peaked at #11 in South Korea, currently #11 in South Korea.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| South Korea | — | #11 | #11 | — |
| TW | — | #11 | #11 | — |
| GR | — | #14 | #14 | — |
| South Africa | — | #33 | #33 | — |
| SG | — | #36 | #36 | — |
| CZ | — | #40 | #40 | — |
| HK | — | #41 | #41 | — |
| Japan | — | #42 | #42 | — |
| BE | — | #50 | #50 | — |
| Sweden | — | #51 | #51 | — |
| Finland | — | #59 | #59 | — |
| CH | — | #65 | #65 | — |
| South Korea | — | #78 | #78 | — |
| PT | — | #80 | #80 | — |
| India | — | #85 | #85 | — |
| AT | — | #91 | #91 | — |
| TW | — | #98 | #98 | — |
| Norway | — | #100 | #100 | — |
| GR | — | #102 | #102 | — |
| United States | — | #109 | #109 | — |
Chart Positions
25 placements across 22 markets.
Chart Positions
25 placements across 22 markets.